Pfizer deals extend patent life for a top-selling rare disease drug
Source ↗
👁 0
💬 0
Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.
Comments (0)